HSIC vs SPRO · P/E 24, rev $12.67B vs P/E 9.6, rev $48.0M
Henry Schein Inc (HSIC) versus Spero Therapeutics Inc (SPRO) — a side-by-side from cached financials, not a winner call.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Spero Therapeutics Inc (SPRO) is a biotechnology company listed on NASDAQ.
Latest reported HSIC revenue for 2024-12-28 was $12.67B. Net income was $398.0M. Revenue was up 2.7% from 2023-12-30 to 2024-12-28. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Latest reported SPRO revenue for 2024-12-31 was $48.0M. Net income was -$68.6M. Revenue was down 53.8% from 2023-12-31 to 2024-12-31. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
HSIC currently screens at market cap $9.11B and trailing P/E 24.2. SPRO currently screens at market cap $149.5M and trailing P/E 9.6.
Not investment advice. Open the HSIC and SPRO stock pages for the full models.
Not investment advice.